SCHEMBL5658885

SCHEMBL5658885

COc1cc(F)c[c]c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
CYP3A4 P08684 1/20 0.35
MPO P05164 2/20 0.33
MAOB P27338 1/20 0.33
HMGCR P04035 1/20 0.33
NFE2L2 Q16236 2/20 0.33
ALOX5 P09917 2/20 0.33
PTGES O14684 1/20 0.33
PTGS1 P23219 1/20 0.33
STAT3 P40763 1/20 0.33
HTT P42858 3/20 0.32
DUSP3 P51452 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32
CA12 O43570 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9160971 0.78 CYP3A4 (0.48) MAPTCYP3A4MAOBALOX5PTGS1
SCHEMBL2349793 0.78 NFE2L2 (0.33) MAPTCYP3A4NFE2L2PTGS1
SCHEMBL1639475 0.77 ERN1 (0.43) MAPTCYP3A4MAOBHTTKDM4E
SCHEMBL10689989 0.77 ACHE (0.43) MAPTCYP3A4MAOBALOX5KDM4E
SCHEMBL2164186 0.77 CA12 (0.41) MAPTCYP3A4MAOBALDH1A1MAPK1
SCHEMBL2346830 0.75 CYP3A4 (0.33) MAPTCYP3A4MAOBNFE2L2KDM4E
SCHEMBL3594844 0.75 ERN1 (0.42) MAPTCYP3A4MAOBALOX5HTT
SCHEMBL11606239 0.72 TNKS2 (0.40) CYP3A4ALOX5KDM4EALDH1A1LMNA
SCHEMBL4438220 0.72 LMNA (0.60) MAPTCYP3A4HTTALDH1A1MEN1
SCHEMBL28640540 0.72 PTGS2 (0.48) HMGCRALOX5HTTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 MAPT 3588/4885CYP3A4 1337/4885MPO 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.